Supplementary Materials

Supplementary Material for:

Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection

Shanshan He, Billy Lin, Virginia Chu, Zongyi Hu, Xin Hu, Jingbo Xiao, Amy Q. Wang, Cameron J. Schweitzer, Qisheng Li, Michio Imamura, Nobuhiko Hiraga, Noel Southall, Marc Ferrer, Wei Zheng, Kazuaki Chayama, Juan J. Marugan, T. Jake Liang*

*Corresponding author. E-mail: jliang{at}nih.gov

Published 8 April 2015, Sci. Transl. Med. 7, 282ra49 (2015)
DOI: 10.1126/scitranslmed.3010286

This PDF file includes:

  • Materials and Methods
  • Fig. S1. CCZ does not affect the expression levels or cellular distribution of HCV entry factors.
  • Fig. S2. Synergistic antiviral effects of CCZ in combination with anti-HCV drugs.
  • Fig. S3. Antiviral activity of CCZ against dengue virus.
  • Table S1. Structure, anti-HCV activity, and cytotoxicity of H1-antihistamine compounds from the NPC library.
  • Table S2. Negligible amount of transformation of (S)-CCZ to (S)-nor-CCZ in vitro.
  • Table S3. Antiviral activity of CCZ against HCV genotypes 1 to 7.
  • Table S4. NIAID antiviral screen of CCZ against 13 viruses.
  • References (41–49)

[Download PDF]